This Site is Intended for US Health Care Professionals Only.

Erwinaze Web Site
Under Construction
Please see full Prescribing Information
If you are interested in ordering Erwinaze, please contact the Accredo Health Group, Inc. at 1-877-900-9223 or complete the order form and fax it to 1-866-628-8942. If you have any questions regarding Erwinaze, please contact Jazz Pharmaceuticals Customer Service at 1-800-833-3533 or

For additional product information, please see the Erwinaze Pharmacy Guide.
JumpStart is your single point of contact for coverage and reimbursement support. To get started, contact us at 1-888-837-4397 or complete the authorization form and email to

Erwinaze® (asparaginase Erwinia chrysanthemi) for injection, 10,000 International Units/vial is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.


Erwinaze is contraindicated in patients with a history of:


Warnings and Precautions

Hypersensitivity Reactions
After the use of Erwinaze in clinical trials, grade 3 and 4 hypersensitivity reactions have occurred in 5% of patients and anaphylaxis occurred in 0,8% of patients. Administer in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis. If a serious hypersensitivity reaction occurs (including anaphylaxis), discontinue Erwinaze and initiate appropriate therapy

In clinical trials, 4% of patients reported pancreatitis with Erwinaze therapy. Discontinue Erwinaze for severe or hemorrhagic pancreatitis manifested by abdominal pain >72 hours and amylase elevation ≥2.0 x ULN. In case of mild pancreatitis, hold Erwinaze until the signs and symptoms subside and amylase levels return to normal. After resolution, Erwinaze therapy may be resumed.

Glucose Intolerance
In clinical trials, 4% of patients reported glucose intolerance, which in some cases may be irreversible. Monitor glucose levels at baseline and periodically during treatment. Administer insulin therapy as necessary in patients with hyperglycemia.

Thrombosis and Hemorrhage
Serious thrombotic events, including sagittal sinus thrombosis have been reported in both E. coli and Erwinia-derived L-asparaginase therapy. Discontinue Erwinaze for a thrombotic or hemorrhagic event until symptoms resolve; after resolution, Erwinaze therapy may be resumed.

Most Common Adverse Reactions
The most common adverse reactions (incidence 1% or greater) with Erwinaze treatment are systemic hypersensitivity, hyperglycemia, abnormal transaminases, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.